3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

INTERACTION BETWEEN ATAZANAVIR AND FOSAMPRENAVIR IN THE TREATMENT OF HIV-INFECTED PATIENTS

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePe3.3C11

Khanlou H., Bhatti L., Farthing C.
AIDS Healthcare Foundation, Los Angeles, United States of America

INTRODUCTION: The use of double-boosted PI regimens may offer benefits, including pharmacokinetic enhancement, a high genetic barrier virus, and probably synergistic activity against HIV. The combination of fosAmprenavir (fosAPV) and atazanavir (ATV) could meet these criteria. Given that fosAPV is an inducer of CYP-3A4 metabolism, potential dosing alterations may be warranted.

METHODS: Trough concentrations (TC) of ATV and APV were obtained in 9 pts receiving combination of ATV150/fosAPV700/RTV100 BID and in 5 pts receiving ATV200/fosAPV700/RTV100 BID for at least 2 weeks. The TCs were analyzed using a centralized laboratory with validated techniques (Consolidated Laboratory Services, Van Nuys, CA). The minimum TC of ATV and APV were defined respectively as 0.27 mcg/ml and 0.28 mcg/ml.

RESULTS: None of the pts were receiving concomitant NNRTIs. 9 of 14 pts on boosted regimens were receiving TDF 300-mg qd. Overall clinical tolerance was excellent. One pt developed grade 3 hyperlipidemia and stopped RTV, with improvement.

CONCLUSIONS: These results appear to indicate that a combination of atazanavir 150 or 200 mg BID and fos-amprenavir 700 mg BID with low dose RTV could offer adequate TCs for both drugs.

Download PDF of this abstract.

050724
Clinical | WePe3.3C11 | Homayoun Khanlou
Drug Interactions

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.